1. Home
  2. HTCR vs PHGE Comparison

HTCR vs PHGE Comparison

Compare HTCR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$3.23

Market Cap

6.5M

Sector

Technology

ML Signal

HOLD

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.71

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTCR
PHGE
Founded
2009
2015
Country
Japan
United States
Employees
N/A
57
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
7.5M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
HTCR
PHGE
Price
$3.23
$0.71
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
52.6K
299.8K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
87.84%
N/A
EPS Growth
414.29
N/A
EPS
0.22
N/A
Revenue
$30,407,229.00
N/A
Revenue This Year
$123.26
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.84
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.25
52 Week High
$3.97
$8.50

Technical Indicators

Market Signals
Indicator
HTCR
PHGE
Relative Strength Index (RSI) 60.89 22.34
Support Level $0.30 $0.43
Resistance Level $3.97 $2.35
Average True Range (ATR) 0.35 0.16
MACD -0.09 0.03
Stochastic Oscillator 54.59 5.43

Price Performance

Historical Comparison
HTCR
PHGE

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: